KORU Medical Systems (KRMD) delivered a quarter that was strong on profitability and weaker on growth. The company reported breakeven earnings of $0.00 per share, in line with consensus. That compares with a $0.02 loss a year earlier, which Earnings Whispers records as 100.0% earnings growth. Revenue of $11.57 million beat the $11.31 million consensus by 2.3% and rose 11.2% year over year. The central tension is that margins and earnings are moving one way while revenue moves the other. Gross margin reached management's 65% long-term target, yet top-line growth slowed for the third straight quarter, from 22% in Q1 to 18% in Q2 to 11% in Q3. Revenue also slipped sequentially from $12.0 million in Q2.

The profit improvement looks genuine. Gross margin expanded to 65.2% from 60.2% a year ago, 61.5% in Q1 and 65.1% in Q2. Management credited lower manufacturing costs, favorable geographic pricing mix, tariff-related rebates and the Q2 contract-manufacturer extension. Operating expenses rose only 3.2%, and the increase came almost entirely from research and development headcount. As a result, a $0.9 million operating loss became $0.19 million of operating income, and GAAP net income was $0.2 million. Adjusted EBITDA, which adds back $0.9 million of stock compensation, jumped to $1.3 million from $0.1 million, or $0.02 per adjusted diluted share. This was the second consecutive quarter of positive net income and adjusted EBITDA, and year-to-date adjusted EBITDA reached $2.2 million versus $0.1 million.

The revenue detail takes more work to interpret. Reported domestic core growth of 31.6% and an international decline of 16.5% are both distorted by a prior-year distributor routing issue: a U.S. distributor had bought KORU products through an international distributor. On a normalized basis, domestic core grew about 10% and international about 23%, with total core up 13.5%. That normalized domestic figure is below the roughly 12% reported in the first half, which is a modest but real slowdown in the core U.S. franchise. Pharma services and clinical trials revenue fell 27%, following a 35% decline in Q2. Management acknowledged that 11% growth was below where it wants to be. It attributed part of the slowdown to the timing of entry into a competitive non-tender European market.

Guidance was narrowed rather than raised outright, and the details point in different directions:

• **Revenue:** the full-year range is now $48.0–48.5 million, up from $47.5–48.5 million. The midpoint moved higher, but the range remains well short of the $50 million high end set in Q1.
• **Gross margin:** the range rose to 63–64%.
• **Cash:** the year-end target increased to more than $8.0 million.

The revenue range implies a Q4 of roughly $12.6–13.1 million and a return to high-teens growth. That reacceleration is back-end loaded and depends heavily on the ramp of the new pan-European partner, which has received its first order, and an Africa partner that shipped an initial order in Q3. The cash target is similarly demanding. Cash fell to $7.4 million after $0.9 million of Q3 usage tied to an inventory build, so management needs at least $0.6 million of positive Q4 cash flow to meet the goal.

The longer-term pipeline offered real support for the growth story:

• Three U.S. specialty pharmacies are now dispensing KORU products for Rystiggo home administration.
• Takeda's pivotal trial of a facilitated 20% SCIG met its primary endpoint against HyQvia.
• An enzyme replacement therapy partner is dosing Phase 3 patients on the Freedom system.
• A nephrology partner signed a follow-on statement of work for international Phase 3 trials.
• The Freedom360 510(k) remains on track for submission by year-end, and connected monitoring technology has reached a functional prototype.

The delays are equally real. Deferoxamine clearance is still pending, with any contribution now framed as 2027 or later. U.S. oncology details have been deferred to the first half of 2027 after the Q2 Fesgo withdrawal. Management also provided no 2027 framework, and international growth depends partly on distributors rebuilding inventory.

Investors entered the report clearly discouraged. Earnings Whispers sentiment fell sharply from a slightly positive 0.09 to -0.67. The stock traded at $3.23 ahead of the release, down 16.2% from the $3.86 open after the August report. Shares were about 18% below the 200-day moving average of $3.95 and roughly 17% beneath the inter-earnings high set the day after the last report. They hit a 52-week low of $2.86 on October 1 and have since recovered about 13% from it. Among the trend readings, sequential growth and AVWAP are positive while price and momentum are neutral. That suggests the selling pressure has eased without a clear shift in direction.

The bottom line is that KORU has largely proven it can be profitable at its current scale, with 65% gross margins and positive adjusted EBITDA. Its growth story, however, now rests on a single quarter. The narrowed guidance and new distribution deals make a Q4 reacceleration credible, and deeply negative sentiment means expectations are already low. Still, three consecutive quarters of deceleration, a reduced revenue ceiling and a thinner cash cushion give skeptics legitimate grounds to wait for proof.